Cargando…
Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass
Cachexia is a complex wasting syndrome that overwhelmingly affects the majority of late-stage cancer patients. Additionally, there are currently no efficacious therapeutic agents to treat the muscle atrophy induced by the cancer. While several preclinical studies have investigated the molecular sign...
Autores principales: | Straughn, Alex R., Kelm, Natia Q., Kakar, Sham S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947350/ https://www.ncbi.nlm.nih.gov/pubmed/33718372 http://dx.doi.org/10.3389/fcell.2021.636498 |
Ejemplares similares
-
Withaferin A attenuates ovarian cancer-induced cardiac cachexia
por: Kelm, Natia Q., et al.
Publicado: (2020) -
Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling
por: Straughn, Alex R., et al.
Publicado: (2019) -
Withaferin A: a potential therapeutic agent against COVID-19 infection
por: Straughn, Alex R., et al.
Publicado: (2020) -
Editorial: Emerging Mechanisms for Skeletal Muscle Mass Regulation
por: Ogura, Yuji, et al.
Publicado: (2021) -
LINCing Nuclear Mechanobiology With Skeletal Muscle Mass and Function
por: van Ingen, Maria J. A., et al.
Publicado: (2021)